A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study
Yusuke Chihara, Takayuki Takeda, Yasuhiro Goto, Yoichi Nakamura, Yuko Tsuchiya-Kawano, Akira Nakao, Keisuke Onoi, Makoto Hibino, Minoru Fukuda, Ryoichi Honda, Takahiro Yamada, Ryusuke Taniguchi, Sinjiro Sakamoto, Koji Date, Seiji Nagashima, Shigeru Tanzawa, Koichi Minato, Koichi Nakatani, Miiru Izumi, Takayuki Shimose
研究成果: ジャーナルへの寄稿 › 学術誌 › 査読
2
被引用数
(Scopus)